Drugs.com - New Drug Approvals

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), as the first and only fixed-dose, intravenous...

Feb 10, 2025 - 01:18
 0
FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), as the first and only fixed-dose, intravenous...
Read More

Tags:

Previous Article

Minor partners with Fliggy’s new ‘Global Discovery’ platform to drive growth and...

Next Article

A Life Aquatic: Absolute’s Navetta 53

Related Posts

FDA Approves Vtama (tapinarof) Cream for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

FDA Approves Vtama (tapinarof) Cream for the Treatment ...

Feb 9, 2025  0

FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Do...

Feb 9, 2025  0

FDA Approves Attruby (acoramidis) to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Patients with ATTR-CM

FDA Approves Attruby (acoramidis) to Reduce Cardiovascu...

Feb 9, 2025  0